Thinking a lot of the 400+ reps didn’t have much of a choice to join/accept, esp due to layoffs. To that, thankful to be back in pharma after a short hiatus. But yes, this “contract” probably pales in comparison to a lot of others. Not fond of the scenario. Pressure seems to definitely be mounting from micromanaging perspective. Would not doubt AT ALL if territories are dissolved after August script deadline, or at least restructuring. Feels like either you meet the Rx goal, keep job longer. If you don’t, then here’s the door. I’d suggest to definitely keep options open, especially in neuroscience , oncology, etc. Hopefully this won’t get ugly before better. But to say the least, summer will seem like we’re all in the frying pan with the mounting pressure.